Dr. Pouliot obtained doctorates in medicine (M.D.) and in Physiology-Endocrinology (Ph.D.) from Laval University. After completing a residency in Urology (F.R.C.S.C.), he did a post-doctoral fellowship in Urologic Oncology and molecular imaging at the University of California, Los Angeles (UCLA). Since 2010, he has practiced as a urologist-oncologist in the Quebec City University Hospital Center. He is also an associate professor in Laval University’s Department of surgery. He oversees the CHU de Québec multidisciplinary clinic in castration-resistant prostate cancer. In 2014, he was the recipient of the Prostate Cancer Canada/Movember Rising Star Award. He is also the recipient of the FRQS Clinical Research Scholars Junior 1 and 2 and Senior. His clinical and preclinical research interests include the detection and characterization of high risk, advanced and metastatic prostate cancers using transcriptional amplification systems or positron emission tomography (PET) with tracers such as fluoro-deoxyglucose or PSMA ligands (PyL, MP-1404).  He is also involved in the development of new radioligand therapeutics.

His research program has four aims: 1) To develop a dynamic imaging method based on a transcriptional amplification system allowing the sensitive detection of a luminescent reporter gene under the control of prostate cancer specific promoters. This microscopy method will allow predicting the patient’s response to antiandrogen treatments. 2) Use positron emission tomography imaging (PET/CT) as a quantitative method to identify the very high risk prostate cancer and to assess metastasis individual response, in addition to global response to systemic treatment. 3) Develop a prostate cancer immunotherapy based on a transcriptional amplification system specific to prostate cancer. This vaccine vector will allow the introduction of recombinant genes in patient’s prostate cancer cells to induce an efficient immune response against cancer cells.  4) Characterize the androgen receptor (AR) activation in castration resistant prostate cancer patients. This project aims to determine which steroids activate the AR under chemical castration and to identify new AR interacting partners using proteomics.

L'Hôtel-Dieu de Québec
6, rue McMahon
0624
Québec, Québec
Canada G1R 2J6
71 entries « 1 of 8 »

Saad F, Fleshner N, Pickles T, Niazi T, Lukka H, Pouliot F, Martins I, Klotz L

Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer.

Journal Article

J Urol, pp. 101097JU0000000000000809, 2020, ISSN: 0022-5347.

Abstract | Links:

Vaillancourt J, Turcotte V, Caron P, Villeneuve L, Lacombe L, Pouliot F, Levesque E, Guillemette C

Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation.

Journal Article

Drug Metab Dispos, 48 (2), pp. 75-84, 2020, ISSN: 0090-9556.

Abstract | Links:

So AI, Chi KN, Danielson B, Fleshner NE, Kapoor A, Niazi T, Pouliot F, Rendon RA, Shayegan B, Sridhar S, Vigneault E, Saad F

Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer.

Journal Article

Can Urol Assoc J, 14 (2), pp. 17-23, 2020, ISSN: 1911-6470.

| Links:

Meziou S, Ringuette Goulet C, Hovington H, Lefebvre V, Lavallee E, Bergeron M, Brisson H, Champagne A, Neveu B, Lacombe D, Beauregard JM, Buteau FA, Riopel J, Pouliot F

GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome.

Journal Article

Prostate Cancer Prostatic Dis, 2020, ISSN: 1365-7852.

Abstract | Links:

Kushnir I, Kirk L, Mallick R, Kim RH, Graham GE, Breau RH, Lattouf JB, Violette PD, Pautler SE, Care M, Kapoor A, Jewett MAS, Wood L, Tanguay S, Heng DYC, Basappa NS, So A, Pouliot F, Reaume NM

Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database.

Journal Article

Clin Oncol (R Coll Radiol), 32 (1), pp. e10-e15, 2020, ISSN: 0936-6555.

Abstract | Links:

Pouliot F, Rouleau M, Neveu B, Toren P, Morin F, Velot L, Ding K, Caron P, Lacombe L, Levesque E, Klotz L, Guillemette C

Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy.

Journal Article

J Urol, pp. 101097JU0000000000000699, 2019, ISSN: 0022-5347.

Abstract | Links:

Lavallee LT, McAlpine K, Kapoor A, Pouliot F, Mason R, Violette PD, Bansal RK, Richard PO, Karakiewicz PI, Bhindi B, Maloni R, Pautler S, Lattouf JB, Kassouf W, Tanguay S, So A, Rendon RA, Breau RH

Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of renal mass biopsy in the management of kidney cancer.

Journal Article

Can Urol Assoc J, 13 (12), pp. 377-383, 2019, ISSN: 1911-6470.

| Links:

Lavallee E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F

Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration.

Journal Article

Eur Urol Focus, 5 (6), pp. 998-1006, 2019.

Abstract | Links:

Wong ECL, Di Lena R, Breau RH, Pouliot F, Finelli A, Lavallee LT, So A, Tanguay S, Fairey A, Rendon R, Richard PO, Lattouf JB, Kawakami J, Mallick R, Kapoor A

Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2.

Journal Article

Urol Oncol, 37 (10), pp. 721-726, 2019, ISSN: 1078-1439.

Abstract | Links:

Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North SA, Pouliot F, Rendon RA, Shayegan B, Sridhar SS, So A, Usmani N, Vigneault E, Chi KN

2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).

Journal Article

Can Urol Assoc J, 13 (10), pp. 307-314, 2019, ISSN: 1911-6470.

| Links:

71 entries « 1 of 8 »
Signaler des ajouts ou des modifications

Active projects

  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • National Program on Radioligand Therapy for Prostate Cancer, Subvention, Cancer de la prostate Canada, from 2018-01-01 to 2022-12-31
  • Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapie ciblée, Subvention, Fonds de recherche du Québec - Santé, ONCOPOLE EMC2: Équipes multi-institutionnelles contre le cancer, from 2018-04-01 to 2021-03-31
  • Utilisation de l’imagerie moléculaire par microscopie à bioluminescence ou par tomographie par émission de positrons afin d’optimiser les stratégies thérapeutiques des patients atteints de cancers urologiques, Subvention, Fonds de recherche du Québec - Santé, Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, from 2019-07-01 to 2023-06-30

Recently finished projects

  • (FRSQ 78541)CUA‐CUOG Astellas Research Grant Program, Subvention, Canadian Urologic Oncology Group, from 2017-06-07 to 2018-06-06
  • (FRSQ 78573) Recherche sur la technique de microscopie bioluminescence pour cancers prostatiques, Subvention, Fondation du CHU de Québec, from 2017-07-10 to 2018-07-09
  • (FRSQ 82588) soutien du projet de recherche sur le cancer de la prostate - Urologie recherche - CHU, Subvention, Fondation du CHU de Québec, from 2018-09-13 to 2019-03-31
  • (FRSQ 82592)Soutien du projet de recherche pour le cancer de la prostate, Subvention, Fondation du CHU de Québec, from 2018-09-13 to 2019-03-31
  • (FRSQ 84874) Support statistique pour la recherche en Urologie-oncologie, Subvention, Fondation du CHU de Québec, from 2019-03-25 to 2020-03-24
  • Development of a urine-based prostate cancer cell bioluminescence imaging nanotechnology for single cell transcriptional characterization, Subvention, Société de recherche sur le cancer, Subvention de fonctionnement, from 2016-09-01 to 2018-08-31
  • Développement et utilisation de systèmes d’amplification transcriptionnelle multigéniques à des fins diagnostiques et thérapeutiques pour améliorer la prise en charge du cancer de la prostate., Subvention, Fonds de recherche du Québec - Santé, Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, from 2017-07-01 to 2019-06-30
Data provided by the Université Laval research projects registery